These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 16373008)

  • 1. Immunotherapy and therapeutic vaccines in HIV infection.
    García F; Ruiz L; López-Bernaldo de Quirós JC; Moreno S; Domingo P
    Enferm Infecc Microbiol Clin; 2005 Jul; 23 Suppl 2():84-104. PubMed ID: 16373008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune therapy: non-highly active antiretroviral therapy management of human immunodeficiency virus-infected patients.
    Mitsuyasu R
    J Infect Dis; 2002 May; 185 Suppl 2():S115-22. PubMed ID: 12001032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term persistence of vaccination and HAART to human immunodeficiency virus (HIV).
    Boström AC; Hejdeman B; Matsuda R; Fredriksson M; Fredriksson EL; Bratt G; Sandström E; Wahren B
    Vaccine; 2004 Apr; 22(13-14):1683-91. PubMed ID: 15068851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune reconstitution in HIV-1-infected patients.
    Imami N; Hardy G; Pires A; Burton C; Pido-Lopez J; Mela C; Gotch F
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1138-45. PubMed ID: 12211404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial.
    Gudmundsdotter L; Wahren B; Haller BK; Boberg A; Edbäck U; Bernasconi D; Buttò S; Gaines H; Imami N; Gotch F; Lori F; Lisziewicz J; Sandström E; Hejdeman B
    Vaccine; 2011 Jul; 29(33):5558-66. PubMed ID: 21300092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy as an adjunct to highly-active antiretroviral therapy.
    Murphey-Corb M; Heydenburg-Fuller D
    Curr Opin Investig Drugs; 2001 Sep; 2(9):1191-7. PubMed ID: 11717803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immune-based therapies and HIV infection].
    Weiss L
    Ann Med Interne (Paris); 2002 Jun; 153(4):227-36. PubMed ID: 12218888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.
    Oxenius A; Price DA; Günthard HF; Dawson SJ; Fagard C; Perrin L; Fischer M; Weber R; Plana M; García F; Hirschel B; McLean A; Phillips RE
    Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13747-52. PubMed ID: 12370434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for AIDS virus infections: cautious optimism for cell-based vaccine.
    Bhardwaj N; Walker BD
    Nat Med; 2003 Jan; 9(1):13-4. PubMed ID: 12514710
    [No Abstract]   [Full Text] [Related]  

  • 11. Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment.
    Calarota SA; Leandersson AC; Bratt G; Hinkula J; Klinman DM; Weinhold KJ; Sandström E; Wahren B
    J Immunol; 1999 Aug; 163(4):2330-8. PubMed ID: 10438897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment interruptions in HIV-infected subjects.
    Bongiovanni M; Casana M; Tincati C; d'Arminio Monforte A
    J Antimicrob Chemother; 2006 Sep; 58(3):502-5. PubMed ID: 16816398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Failure to reconstitute CD4+ T-cells despite suppression of HIV replication under HAART.
    Aiuti F; Mezzaroma I
    AIDS Rev; 2006; 8(2):88-97. PubMed ID: 16848276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of virus-specific immune responses in SHIV(KU)-infected macaques treated with PMPA.
    Kumar A; Buch S; Foresman L; Bischofberger N; Lifson JD; Narayan O
    Virology; 2001 Jan; 279(1):97-108. PubMed ID: 11145893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A model predictive control based scheduling method for HIV therapy.
    Zurakowski R; Teel AR
    J Theor Biol; 2006 Jan; 238(2):368-82. PubMed ID: 15993900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of antiretroviral immunotherapy trials with potentially non-normal and incomplete longitudinal data.
    Mogg R; Mehrotra DV
    Stat Med; 2007 Feb; 26(3):484-97. PubMed ID: 16625520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving immune function and controlling viral replication in HIV-1-infected patients with immune-based therapies.
    Angel JB
    AIDS Read; 2001 Apr; 11(4):209-21. PubMed ID: 11392678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Various approaches of therapeutic vaccination for the treatment of HIV type 1 infection].
    Lazrek M; Lobert PE; Goffard A; Schanen C; Dewilde A; Bocket L; Hober D
    Ann Biol Clin (Paris); 2005; 63(6):581-8. PubMed ID: 16330376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A primer on HIV type 1-specific immune function and REMUNE.
    Moss RB; Giermakowska WK; Savary JR; Theofan G; Daigle AE; Richieri SP; Jensen FC; Carlo DJ
    AIDS Res Hum Retroviruses; 1998 Jun; 14 Suppl 2():S167-75. PubMed ID: 9672235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trial suggests vaccines could aid HIV therapy.
    Check E
    Nature; 2003 Apr; 422(6933):650. PubMed ID: 12700722
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.